Leerink Swann Upgrades Vivus (VVUS) to Outperform; Becoming A More Attractive Asset For Big Pharma After Qnexa Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. IBM
2. SPY
3. LCID
4. JPM
5. ERAS
6. BAC
7. TREX
8. AAPL
9. ORCL
10. SKHY

Go back to Leerink Swann Upgrades Vivus (VVUS) to Outperform; Becoming A More Attractive Asset For Big Pharma After Qnexa Approval